Cover Image
市場調查報告書

亨丁頓舞蹈症治療藥的全球市場預測 2018-2028年:抗多巴胺藥、抗精神病藥、抗痙攣藥、抗憂鬱症藥

Global Huntington's Disease Drugs Market Forecast 2018-2028: Forecasts by Drug Class (Antidopaminergics, Antipsychotics, Anticonvulsants, Antidepressants), with Analysis for Leading Drugs, Leading Companies & Promising Pipeline Molecules

出版商 Visiongain Ltd 商品編碼 608854
出版日期 內容資訊 英文 163 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
亨丁頓舞蹈症治療藥的全球市場預測 2018-2028年:抗多巴胺藥、抗精神病藥、抗痙攣藥、抗憂鬱症藥 Global Huntington's Disease Drugs Market Forecast 2018-2028: Forecasts by Drug Class (Antidopaminergics, Antipsychotics, Anticonvulsants, Antidepressants), with Analysis for Leading Drugs, Leading Companies & Promising Pipeline Molecules
出版日期: 2018年01月12日 內容資訊: 英文 163 Pages
簡介

本報告提供全球亨丁頓舞蹈症治療藥市場相關分析,疾病概要,市場區隔、各地區/國家的市場趨勢預測,市場定性分析,有未來潛力的開發平台分子,主要企業的簡介的資訊彙整,為您概述為以下內容。

第1章 調查概要

第2章 亨丁頓舞蹈症的簡介

  • 亨丁頓舞蹈症的原因和風險因素是什麼?
  • 亨丁頓舞蹈症的症狀
  • 亨丁頓舞蹈症的診斷
  • 亨丁頓舞蹈症的治療
  • 亨丁頓舞蹈症的流行病學
  • 社會、經濟負擔
  • 全球亨丁頓舞蹈症的簡介

第3章 全球亨丁頓舞蹈症治療藥市場規模、預測:各類藥物

  • 市場區隔:各用途
  • 全球抗多巴胺藥市場
  • 全球抗精神病藥市場
  • 全球抗痙攣藥市場
  • 全球抗憂鬱症藥市場
  • 全球及其他的亨丁頓舞蹈症治療藥市場

第4章 全球亨丁頓舞蹈症市場上主要治療藥

  • Xenazine (Tetrabenazine)
  • Austedo (Deutetrabenazine)
  • Clozapine
  • Haloperidol
  • Abilify
  • Risperdal

第5章 主要國家市場預測

  • 全球亨丁頓舞蹈症治療藥市場地區結構
  • 南北美洲的亨丁頓舞蹈症治療藥市場
  • EU5個國家的亨丁頓舞蹈症治療藥市場
  • 其他 (ROW) 的亨丁頓舞蹈症治療藥市場

第6章 亨丁頓舞蹈症治療藥市場定性分析

  • 市場成長的促進要素
  • 市場課題
  • 市場趨勢

第7章 開發平台分子

  • 有未來潛力的開發平台分子

第8章 主要企業

  • Hoffmann-La Roche Ltd.
  • H. Lundbeck
  • Teva Pharmaceutical Industries Ltd.
  • Prana Biotechnology
  • Sangamo Therapeutics Inc.
  • Horizon Pharma Plc.
  • Omeros Corp.
  • Valeant Pharmaceuticals International Inc.

第9章 摘要整理、建議

第10章 詞彙表

目錄
Product Code: PHA0275

Report Details

  • Do you need definitive Huntington's Disease market data?
  • Succinct Huntington's Disease market analysis?
  • Technological insight?
  • Actionable business recommendations?

Read on to discover how this definitive report can transform your own research and save you time.

The Global Huntington's Disease market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.

Lastly, the study of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy and producing disease modifying drugs.

Report highlights

  • 77 quantitative tables, charts, and graphs across 163 pages
  • Global Huntington's Disease market outlook and analysis from 2018-2028
  • Global Huntington's Disease submarket forecasts and analysis from 2018-2028
    • Antidopaminergics
    • Antipsychotics
    • Anticonvulsants
    • Antidepressants
    • Other
  • Regional and National Huntington's Disease market forecasts 2018-2028
    • North America forecast 2018-2028
    • US forecast 2018-2028
    • Rest of North America forecast 2018-2028
    • Europe forecast 2018-2028
    • Germany forecast 2018-2028
    • UK forecast 2018-2028
    • France forecast 2018-2028
    • Italy forecast 2018-2028
    • Spain forecast 2018-2028
    • Rest of Europe forecast 2018-2028
  • Rest of World forecast 2018-2028

Key questions answered

  • What does the future hold for the Pharmaceutical industry with regards to Huntington's Disease
  • Where should you target your business strategy?
  • Which applications should you focus upon?
  • Which disruptive technologies should you invest in?
  • Which companies should you form strategic alliances with?
  • Which company is likely to success and why?
  • What business models should you adopt?
  • What industry trends should you be aware of?

Target audience

  • Leading Pharmaceutical companies
  • Suppliers
  • Contractors
  • Technologists
  • R&D staff
  • Consultants
  • Analysts
  • CEO's
  • CIO's
  • COO's
  • Business development managers
  • Investors
  • Governments
  • Agencies
  • Banks

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Why You Should Read This Report
  • 1.2. How This Report Delivers
  • 1.3. Key Questions Answered by This Analytical Report Include:
  • 1.4. Who is This Report For?
  • 1.5. Methodology
    • 1.5.1. Primary Research
    • 1.5.2. Secondary Research
    • 1.5.3. Market Evaluation & Forecasting Methodology
  • 1.6. Frequently Asked Questions (FAQ)
  • 1.7. Associated Visiongain Reports
  • 1.8. About Visiongain

2. Introduction to Huntington's Disease

  • 2.1. What Are the Causes And Risk Factors Of Huntington's Disease?
    • 2.1.1. Risk Factors
      • 2.1.1.1. Alcohol Intake
      • 2.1.1.2. Pneumonia:
      • 2.1.1.3. Stress
  • 2.2. Symptoms of Huntington's Disease
    • 2.2.1. Symptoms in Adult Onset
    • 2.2.2. Movement Disorders
    • 2.2.3. Cognitive Disorders
    • 2.2.4. Psychiatric Disorders
    • 2.2.5. Symptoms in Juvenile Onset
    • 2.2.6. Behavioural Changes:
  • 2.3. Diagnosis of Huntington's Disease
    • 2.3.1. Neurological Tests:
    • 2.3.2. Brain Function and Imaging Tests:
    • 2.3.3. Genetic Testing:
    • 2.3.4. Psychiatric Tests:
    • 2.3.5. Test in Pregnancy:
    • 2.3.6. Preimplantation Genetic Diagnosis:
  • 2.4. Treatment of Huntington's Disease
    • 2.4.1. Medications for Movement Disorders:
    • 2.4.2. Medications for Psychiatric Disorders:
    • 2.4.3. Psychotherapy
    • 2.4.4. Speech Therapy
    • 2.4.5. Physical Therapy
    • 2.4.6. Occupational Therapy
  • 2.5. Epidemiology of Huntington's Disease
  • 2.6. Social and Economic Burden
    • 2.6.1. Mortality
    • 2.6.2. Morbidity
    • 2.6.3. Economic Impact
  • 2.7. Introduction to the Global Huntington's Disease Market

3. Global Huntington's Disease Market Size And Forecast By Drug Class

  • 3.1. Market Segmentation by Application
  • 3.2. Global Antidopaminergics Market
    • 3.2.1. Market Overview
    • 3.2.2. Market Size and Forecast
  • 3.3. Global Antipsychotics Market
    • 3.3.1. Market Overview
    • 3.3.2. Market Size and Forecast
  • 3.4. Global Anticonvulsants Market
    • 3.4.1. Market Overview
    • 3.4.2. Market Size and Forecast
  • 3.5. Global Antidepressants Market
    • 3.5.1. Market Overview
    • 3.5.2. Market Size and Forecast
  • 3.6. Global Other Huntington's Disease Drugs Market
    • 3.6.1. Market Overview
    • 3.6.2. Market Size and Forecast

4. Leading Drugs in Global Huntington's Disease Market, 2017

  • 4.1. Xenazine (tetrabenazine)
  • 4.2. Austedo (Deutetrabenazine)
  • 4.3. Clozapine
  • 4.4. Haloperidol
  • 4.5. Abilify
  • 4.6. Risperdal

5. Leading National Markets Forecast 2017-2028

  • 5.1. Geographical Breakdown of Global Huntington's Disease Drugs Market, 2016
  • 5.2. Huntington's Disease Drugs Market in the Americas, 2016
  • 5.3. Huntington's Disease Drugs Market in the EU5, 2016
    • 5.3.1. Market Forecast of the EU5 Countries, 2017-2028
    • 5.3.2. The UK
    • 5.3.3. Germany
    • 5.3.4. France
    • 5.3.5. Spain
    • 5.3.6. Italy
    • 5.3.7. Huntington's Disease Drugs Market in the Rest of Europe, 2016
  • 5.4. Huntington's Disease Drugs Market in the Rest of the World, 2016
    • 5.4.1. Japan
    • 5.4.2. China
    • 5.4.3. Russia

6. Qualitative Analysis of the Huntington's Disease Market

  • 6.1. Market Growth Drivers
    • 6.1.1. Unmet Medical Need
    • 6.1.2. Special Regulatory Provisions for Rare Diseases
    • 6.1.3. Designated ICD-10 Code
    • 6.1.4. Increased investment in R&D
    • 6.1.5. Alternative Therapies
  • 6.2. Market Challenges
    • 6.2.1. Poor Diagnosis Rates
    • 6.2.2. Limited Patient Population
    • 6.2.3. Stringent Regulatory Guidelines
    • 6.2.4. Alternative programs for management of mental disorders
  • 6.3. Market Trends
    • 6.3.1. Advances in Biomedical Sciences
    • 6.3.2. Focus on Regenerative Therapies for Mental Disorders
    • 6.3.3. Rising Public Interest Toward Mental Health
    • 6.3.4. Novel Mechanisms Targeted by Pipeline Candidates
    • 6.3.5. Emergence of First-in-class Pipeline Molecules

7. Pipeline Molecules

  • 7.1. Promising Potential Pipeline Molecules
    • 7.1.1. Phase III Molecules
      • 7.1.1.1. Tetrabenazine (Xenazine)
      • 7.1.1.2. Deutetrabenazine (Austedo)
      • 7.1.1.3. PRIDOPIDINE
    • 7.1.2. Phase II Molecules
      • 7.1.2.1. Laquinimod
      • 7.1.2.2. PBT2
      • 7.1.2.3. VX15(SIGNAL)
      • 7.1.2.4. PDE10A Inhibitor
      • 7.1.2.5. Deep Brain Stimulation (DBS)
      • 7.1.2.6. Cysteamine (RP103)
    • 7.1.3. Phase I Molecules
      • 7.1.3.1. Antisense Oligonucleotide Huntingtin Lowering Drug
    • 7.1.4. Phase Pre-Clinical R&D
      • 7.1.4.1. Pre- Cell/HD Cell
      • 7.1.4.2. AAV-SHRNA
      • 7.1.4.3. Zinc Finger DNA-Binding Protein (ZFP)
      • 7.1.4.4. HDAC Inhibitor
      • 7.1.4.5. KMO Inhibitor

8. Leading Companies in Global Huntington's Disease Market, 2017

  • 8.1. Hoffmann-La Roche Ltd.
    • 8.1.1. SWOT Analysis:
  • 8.2. H. Lundbeck
    • 8.2.1. Business Strategy:
    • 8.2.2. SWOT Analysis:
  • 8.3. Teva Pharmaceutical Industries Ltd.
    • 8.3.1. Business Strategy:
    • 8.3.2. SWOT Analysis:
  • 8.4. Prana Biotechnology
  • 8.5. Sangamo Therapeutics Inc.
  • 8.6. Horizon Pharma Plc.
    • 8.6.1. Revenue from Business Units:
    • 8.6.2. Business Strategy:
      • 8.6.2.1. Key Developments:
      • 8.6.2.2. SWOT Analysis:
  • 8.7. Omeros Corp.
    • 8.7.1. SWOT Analysis:
  • 8.8. Valeant Pharmaceuticals International Inc.
    • 8.8.1. Business strategy:
    • 8.8.2. SWOT Analysis

9. Executive Summary and Recommendations

10. Glossary

  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1: Example of Huntington's Disease Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)
  • Figure 2.1: Example of Huntington's Disease Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)
  • Figure 2.2: Global Huntington's Disease Market Segmentation by Drug Class(% Share)
  • Figure 3.1: Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue($m), AGR(%)
  • Figure 3.2: Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue($m), AGR(%)
  • Figure 3.3: Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue($m), AGR(%)
  • Figure 3.4: Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue($m), AGR(%)
  • Figure 3.5: Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue($m), AGR(%)
  • Figure 3.6: Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue($m), AGR(%)
  • Figure 5.1: Global Huntington's Disease Drugs Market Segmentation by Region/Country
  • Figure 5.2: Global Huntington's Disease Drugs Market by Region: Revenue($m)
  • Figure 5.3: Global Huntington's Disease Drugs Market by Region: Market Share 2016(%)
  • Figure 5.4: Global Huntington's Disease Drugs Market by Region: AGR 2017-2028(%)
  • Figure 5.5: Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017-2028(%)
  • Figure 5.6: Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017(%)
  • Figure 5.7: Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2022(%)
  • Figure 5.8: Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2027(%)
  • Figure 5.9: Huntington's Disease Drugs Market in the US: 2016 Market Share %
  • Figure 5.10: Huntington's Disease Drugs Market in the US: 2016 Revenue($m), Market Share %
  • Figure 5.11: Huntington's Disease Market Forecast in the US 2017-2028: Revenue($m), AGR(%)
  • Figure 5.12: Huntington's Disease Drugs Market in the EU5 2016: Global Market Share(%)
  • Figure 5.13: Huntington's Disease Drugs Market in the EU5 Countries 2016: Market Share(%)
  • Figure 5.14: Huntington's Disease Drugs Market in the EU5 Countries 2028 Market Share(%)
  • Figure 5.15: Huntington's Disease Drugs Market Forecast in EU5: Revenue($m), AGR(%),2017-2028
  • Figure 5.16: Global Huntington's Disease Drugs Market Forecast in The UK 2017-2028: Revenue($m), AGR(%)
  • Figure 5.17: Global Huntington's Disease Drugs Market Forecast in Germany 2017-2028: Revenue($m), AGR(%)
  • Figure 5.18: Global Huntington's Disease Drugs Market Forecast in France 2017-2028: Revenue($m), AGR(%)
  • Figure 5.19: Global Huntington's Disease Drugs Market Forecast in Spain 2017-2028: Revenue($m), AGR(%)
  • Figure 5.20: Global Huntington's Disease Drugs Market Forecast in Italy 2017-2028: Revenue($m), AGR(%)
  • Figure 5.21: Huntington's Disease Drugs Market Forecast in the RoE: Revenue($m), AGR(%),2017-2028
  • Figure 5.22: Huntington's Disease Drugs Market Forecast in RoW: Revenue($m), AGR(%),2017-2028
  • Figure 8.1: Roche: Sales 2016
  • Figure 8.2: Roche: Sales 2016
  • Figure 8.3: H. Lundbeck: SWOT Analysis 2016
  • Figure 8.4: Teva: SWOT Analysis 2016
  • Figure 8.5: Horizon Revenue by Business Unit
  • Figure 8.6: Horizon: Drugs under Orphan Business Unit:
  • Figure 8.7: Horizon Drugs under Primary Care Unit:
  • Figure 8.8: Horizon: Drugs under Rheumatology Business Unit:
  • Figure 8.9: Horizon SWOT Analysis
  • Figure 8.10: Omeros Corp: SWOT Analysis
  • Figure 8.11: Valeant SWOT Analysis
  • Figure 9.1: Global Huntington's Disease Market Forecast 2017-2028: Revenue($m), AGR(%)

List of Tables

  • Table 1.1: Example of Huntington's Disease Market by Regional Market Forecast 2017-2028(US$m, AGR %, Cumulative)
  • Table 2.1: Prevalence of Huntington's Disease by Geography 2015
  • Table 2.2: Incidence of Huntington's Disease by Geography 2015
  • Table 3.1: Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue($m), AGR(%), CAGR(%)
  • Table 3.2: Global Antidopaminergics Drugs Market Forecast 2017-2028: Revenue($m), AGR(%), CAGR(%)
  • Table 3.3: Global Antipsychotics Drugs Market Forecast 2017-2028: Revenue($m), AGR(%), CAGR(%)
  • Table 3.4: Global Anticonvulsants Drugs Market Forecast 2017-2028: Revenue($m), AGR(%), CAGR(%)
  • Table 3.5: Global Antidepressants Drugs Market Forecast 2017-2028: Revenue($m), AGR(%), CAGR(%)
  • Table 3.6: Global Antidepressants Drugs Market Forecast 2017-2028: Revenue($m), AGR(%), CAGR(%)
  • Table 5.1: Global Huntington's Disease Drugs Market by Region: Revenue($m), and Market Share(%), 2016
  • Table 5.2: Global Huntington's Disease Drugs Market Forecast by Region: Revenue($m), AGR(%), CAGR(%),2017-2028
  • Table 5.3: Global Huntington's Disease Drugs Market by Region: AGR 2017-2028(%)
  • Table 5.4: Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017-2028(%)
  • Table 5.7: Global Huntington's Disease Drugs Market Forecast in the Americas: Revenue($m), AGR(%), CAGR(%),2017-2028
  • Table 5.8: Global Huntington's Disease Drugs Market Forecast by Region: Revenue($m), AGR(%), CAGR(%),2017-2028
  • Table 5.9: Huntington's Disease Drugs Market in the EU5, 2017
  • Table 5.10: Huntington's Disease Drugs Market Forecast in EU5: Revenue($m), AGR(%), CAGR(%), 2017-2028
  • Table 5.11: Huntington's Disease Drugs Market Forecast in UK: Revenue($m), AGR(%), CAGR(%), 2017-2028
  • Table 5.12: Huntington's Disease Drugs Market Forecast in Germany: Revenue($m), AGR(%), CAGR(%), 2017-2028
  • Table 5.13: Huntington's Disease Drugs Market Forecast in France: Revenue($m), AGR(%), CAGR(%), 2017-2028
  • Table 5.14: Huntington's Disease Drugs Market Forecast in Spain: Revenue($m), AGR(%), CAGR(%), 2017-2028
  • Table 5.15: Huntington's Disease Drugs Market Forecast in Italy: Revenue($m), AGR(%), CAGR(%), 2017-2028
  • Table 5.16: Huntington's Disease Drugs Market Forecast in RoE: Revenue($m), AGR(%), CAGR(%), 2017-2028
  • Table 5.17: Huntington's Disease Drugs Market Forecast in Row: Revenue($m), AGR(%), CAGR(%), 2017-2028
  • Table 7.1: Active Pipeline Molecules under Development for Treating Huntington's Disease
  • Table 7.1: Active Pipeline Molecules under Development for Treating Huntington's Disease(Continued)
  • Table 8.1:Roche: Overview 2016
  • Table 8.2: H. Lundbeck: Overview 2016
  • Table 8.3: Teva: Overview 2016
  • Table 8.4: Prana: Overview 2016
  • Table 8.5: Sangamo: Overview 2016
  • Table 8.6: Horizon: Overview 2016
  • Table 8.7: Omeros: Overview 2016
  • Table 8.8: Valeant: Overview 2016

Companies Listed

  • Abbott Laboratories,Inc.,
  • Actavis
  • Aldagen
  • Allergan, Inc
  • Astra Zeneca
  • Auspex Pharmaceuticals Inc
  • Australian Securities Exchange
  • Bausch + Lomb
  • Baxter International, Inc.
  • BioMarin
  • Boston Scientific Corporation
  • BrainCells
  • Bristol-Meyers Squibb
  • Cardinal Health
  • Cephalon Inc.
  • CHDI Foundation
  • Defined Health
  • Dow AgroSciences
  • Eli Lilly
  • F. Hoffmann-La Roche AG
  • Fate Therapeutics
  • Forest Laboratories
  • Gedeon Richter
  • Genzyme
  • Germany Effects
  • Glaxo SmithKline
  • H. Lundbeck
  • Horizon Pharmaceutical LLC.
  • Hospira, Inc
  • InterMune
  • Intra-Cellular Therapies
  • Ionis Pharmaceuticals
  • Isis Pharmaceuticals
  • iZumi Bio.
  • Janssen Pharmaceuticals
  • Johnson & Johnson
  • KDL
  • Lundbeck Pharmaceuticals
  • Lupin
  • Luye Pharma
  • Marnac
  • Medtronic, Inc.
  • Merck Serono
  • MSI Methylation Sciences
  • Mylan Pharmaceuticals
  • Naurex
  • Neuroptix Corporation
  • Novartis AG
  • Omeros Corporation
  • Opko Health
  • Otsuka America Pharmaceutical, Inc.
  • Otsuka Pharmaceutical
  • Ovation Pharmaceuticals
  • Pfizer, Inc.
  • Prana Biotechnology
  • Raptor Pharmaceuticals
  • River Vision Development Corp
  • Sangamo BioSciences, Inc
  • Sangamo Therapeutics
  • Sanofi
  • Shionogi Seiyaku
  • Shire plc
  • Sigma-Aldrich Corporation
  • SK Biopharmaceuticals
  • Teva Pharmaceutical Industries
  • Torrent Pharma
  • UCB Group
  • Vaccinex Inc.
  • Vidara Therapeutics International
  • Voyager Therapeutics Inc

List of Organizations:

  • American Gastroenterological Association (AGA) Institute
  • Anxiety and Depression Association of America
  • Brain and Spinal Cord Institute
  • Centre Hospitalier Universitaire
  • European Huntington's Disease Network (EHDN
  • European Medicines Agency (EMA)
  • FDA's Office of Orphan Products Development
  • FENIN, the Spanish Healthcare Technology Federation
  • Medicaid
  • Ministry of Health, Labor and Welfare (MHLW)
  • Pharmaceutical Research and Manufacturers of America (PhRMA
  • The Centers for Disease Control and Prevention (CDC)
  • The Organisation for Economic Co-operation and Development (OECD)
  • The Scripps Research Institute
  • UK National Health Service (NHS)
  • University Clinic Dusseldorf
  • University of Auckland, New Zealand
  • University of California at Davis
  • US Food & Drug Administration (FDA)
  • World Bank
  • World Health Organisation (WHO)
Back to Top